Geoff Lindeman, a clinician-scientist, is Joint Head of the Cancer Biology and Stem Cells Division at the Walter and Eliza Hall Institute. He is also a medical oncologist at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre and holds an honorary appointment as Professorial Fellow in the Department of Medicine, University of Melbourne. His laboratory is studying molecular and cellular regulators of normal mammary gland development and perturbations that give rise to hereditary and sporadic breast cancer. Recent work has led to the discovery of RANK-positive progenitors as a target for breast cancer prevention in BRCA1 mutation carriers. These findings have contributed to the development of an international breast cancer prevention study. His group has also generated patient derived xenograft (PDX) models that are being used in ‘proof-of-principle’ pre-clinical studies, aimed at transferring promising drugs to the clinic. Lindeman is a Fellow of the Australian Academy of Health and Medical Sciences and the Australian Academy of Science.
Abstracts this author is presenting: